Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increased Expression and Altered Cellular Localization of Fibroblast Growth Factor Receptor-Like 1 (FGFRL1) Are Associated with Prostate Cancer Progression.
Yu L, Toriseva M, Afshan S, Cangiano M, Fey V, Erickson A, Seikkula H, Alanen K, Taimen P, Ettala O, Nurmi M, Boström PJ, Kallajoki M, Tuomela J, Mirtti T, Beumer IJ, Nees M, Härkönen P. Yu L, et al. Among authors: kallajoki m. Cancers (Basel). 2022 Jan 7;14(2):278. doi: 10.3390/cancers14020278. Cancers (Basel). 2022. PMID: 35053442 Free PMC article.
Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.
Yu L, Toriseva M, Tuomala M, Seikkula H, Elo T, Tuomela J, Kallajoki M, Mirtti T, Taimen P, Boström PJ, Alanen K, Nurmi M, Nees M, Härkönen P. Yu L, et al. Among authors: kallajoki m. Int J Cancer. 2016 Jul 1;139(1):140-52. doi: 10.1002/ijc.30048. Epub 2016 Mar 12. Int J Cancer. 2016. PMID: 26891277 Free article.
Stratification of aggressive prostate cancer from indolent disease-Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue.
Alinezhad S, Väänänen RM, Tallgrén T, Perez IM, Jambor I, Aronen H, Kähkönen E, Ettala O, Syvänen K, Nees M, Kallajoki M, Taimen P, Boström PJ, Pettersson K. Alinezhad S, et al. Among authors: kallajoki m. Urol Oncol. 2016 Jun;34(6):255.e15-22. doi: 10.1016/j.urolonc.2015.12.014. Epub 2016 Feb 5. Urol Oncol. 2016. PMID: 26857646 Clinical Trial.
Uptake of 18F-rhPSMA-7.3 in Positron Emission Tomography Imaging of Prostate Cancer: A Phase 1 Proof-of-Concept Study.
Malaspina S, Taimen P, Kallajoki M, Oikonen V, Kuisma A, Ettala O, Mattila K, Boström PJ, Minn H, Kalliokoski K, Postema EJ, Miller MP, Scheinin M. Malaspina S, et al. Among authors: kallajoki m. Cancer Biother Radiopharm. 2022 Apr;37(3):205-213. doi: 10.1089/cbr.2021.0322. Epub 2021 Dec 28. Cancer Biother Radiopharm. 2022. PMID: 34962139 Clinical Trial.
ANO7 is associated with aggressive prostate cancer.
Kaikkonen E, Rantapero T, Zhang Q, Taimen P, Laitinen V, Kallajoki M, Jambulingam D, Ettala O, Knaapila J, Boström PJ, Wahlström G, Sipeky C, Pursiheimo JP, Tammela T, Kellokumpu-Lehtinen PL; PRACTICAL Consortium; Fey V, Maehle L, Wiklund F, Wei GH, Schleutker J. Kaikkonen E, et al. Among authors: kallajoki m. Int J Cancer. 2018 Nov 15;143(10):2479-2487. doi: 10.1002/ijc.31746. Epub 2018 Sep 22. Int J Cancer. 2018. PMID: 30157291 Free PMC article.
New prostate cancer grade grouping system predicts survival after radical prostatectomy.
Erickson A, Sandeman K, Lahdensuo K, Nordling S, Kallajoki M, Seikkula H, Bützow A, Vasarainen H, Boström PJ, Taimen P, Rannikko A, Mirtti T. Erickson A, et al. Among authors: kallajoki m. Hum Pathol. 2018 May;75:159-166. doi: 10.1016/j.humpath.2018.01.027. Epub 2018 Feb 13. Hum Pathol. 2018. PMID: 29447924 Free article. No abstract available.
Altered expression of syndecan-1 in prostate cancer.
Kiviniemi J, Kallajoki M, Kujala I, Matikainen MT, Alanen K, Jalkanen M, Salmivirta M. Kiviniemi J, et al. Among authors: kallajoki m. APMIS. 2004 Feb;112(2):89-97. doi: 10.1111/j.1600-0463.2004.apm1120202.x. APMIS. 2004. PMID: 15056224
Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer.
Haddad BR, Erickson A, Udhane V, LaViolette PS, Rone JD, Kallajoki MA, See WA, Rannikko A, Mirtti T, Nevalainen MT. Haddad BR, et al. Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1642-1651. doi: 10.1158/1055-9965.EPI-18-1358. Epub 2019 Jul 10. Cancer Epidemiol Biomarkers Prev. 2019. PMID: 31292140 Free PMC article.
111 results